- Health Canada Regulatory approval obtained in July for the first fully integrated PFA system with a CARTO™-enabled simple and reproducible workflow.
- Integrated with the world’s leading CARTO™ 3D Cardiac Mapping System for the treatment of symptomatic drug refractory paroxysmal atrial fibrillation (AF).
- Health Canada approval follows recent CE Mark and Japan approval of the VARIPULSE™ Platform.
Johnson & Johnson MedTech, a global leader in arrhythmia treatment, announced the first commercial use of its VARIPULSE™ Platform in Canada. The groundbreaking procedure was successfully completed at the Ottawa Heart Institute, marking a significant milestone in the treatment of atrial fibrillation (AF) in the country.
The VARIPULSE™ Platform is comprised of the VARIPULSE™ Catheter, a multielectrode, regional ablation catheter; the TRUPULSE™ Generator, a multichannel PFA generator; and CARTO™ 3 System, the world’s leading 3D cardiac mapping system. The VARIPULSE™ Platform is the first and only CARTO™ -integrated PFA system, enabling an intuitive and reproducible workflow with real-time visualization and feedback mechanisms, offering enhanced precision and efficiency in AF ablation procedures.
“The VARIPULSE™ Platform, differentiated by its CARTO™ 3 System integration and mapping capabilities, is part of a versatile portfolio of PFA tools that Johnson & Johnson MedTech is developing to meet the varied needs of electrophysiologists and their patients,” said Jasmina Brooks, President, Electrophysiology, Johnson & Johnson MedTech. “Based on the results from the inspIRE clinical trial, we are confident that this innovation has the promise to deliver significant value and differentiated capabilities and become an important tool for the treatment of AF.”
Advancing Atrial Fibrillation Care with PFA Technology
Pulsed Field Ablation is emerging as a transformative technology in electrophysiology. By selectively ablating myocardial tissue while sparing surrounding structures, PFA offers new possibilities for improving procedural safety and patient outcomes. The successful deployment of the VARIPULSE™ Platform in a commercial setting at the Ottawa Heart Institute demonstrates the potential of this technology to redefine AF treatment.
"We are thrilled to have performed the first commercial case in Canada using the VARIPULSE™ Platform. The catheter design is well made, and it allows for a quick and efficient procedure" said Dr. Nairi, Electrophysiologist at the Ottawa Heart Institute. "This novel approach to AF treatment enables us to deliver energy more selectively, offering our patients a more efficient treatment option."
A Key Step Forward in Electrophysiology
The introduction of the VARIPULSE™ Platform in Canada is part of J&J MedTech’s commitment to providing electrophysiologists with advanced tools that enhance procedural outcomes. The catheter is part of the company’s Pulsed Field Ablation (PFA) portfolio, which aims to bring next-generation technologies to the forefront of electrophysiology practices worldwide.
"We are proud to bring the VARIPULSE™ Platform to Canada, enabling electrophysiologists to offer this state-of-the-art treatment to their patients," said James Brodie, General Manager, Johnson & Johnson MedTech. "As we continue to expand our portfolio of innovative solutions, our mission remains clear – to advance the science of electrophysiology and improve the quality of life for patients with AF."
Cardiovascular Solutions from Johnson & Johnson MedTech
Across Johnson & Johnson, we are tackling the world’s most complex and pervasive health challenges. Through a cardiovascular portfolio that provides healthcare professionals with advanced mapping and navigation, miniaturized tech, and precise ablation we are addressing conditions with significant unmet needs such as coronary artery disease, stroke, and atrial fibrillation. We are the global leaders in heart recovery, circulatory restoration and the treatment of heart rhythm disorders, as well as an emerging leader in neurovascular care.
About Johnson & Johnson
At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow, and profoundly impact health for humanity. Learn more about our MedTech sector’s global scale and deep expertise in cardiovascular, orthopedics, surgery and vision solutions at thenext.jnjmedtech.com. Follow us at @JNJMedTech and on LinkedIn.
i: Dr Nair has not been compensated in connection with this announcement
CA_BWI_THER_391575